Lonza dextrometorphan process

Owing to strategic reasons, Lonza exited the dextrometorphan business before the process could be transferred. Subsequently a further study of the hydrogenation of 10, using iridium complexes with chiral amidophosphine-phosphonite ligands, was published by another group [14]. An enantioselectivity of 86% ee was reached, but the chemoselectivity was low. 

---